Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Reuters

11/10

Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma $(BCC)$. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582984141"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582984141\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582984141?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582984141","market":"fut","top_or_hot":-1,"title":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 14:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbR0290:1","article_id":"2582984141","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582984141","pubTimestamp":1762754446,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma . Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8 and helper CD4 T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Troms on November 11, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Lytix Biopharma报告Ruxotemitide治疗基底细胞癌的强劲II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    \n\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma $(BCC)$. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}